Progress of prognosis and treatment of high grade B-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 142-144,147, 2017.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-606273
Biblioteca responsável:
WPRO
ABSTRACT
High grade B-cell lymphoma (HGBL) has been defined as a separate entity in World Health Organization classification in 2016 and is considered to be clinically aggressive. People make continuous analysis of the subgroups and accurate treatments, such as the comparison between the prognosis of HGBL-not otherwise specified and double-hit lymphoma (DHL), transformed and primary DHL, myc partner/bcl-2/bcl-6 translocation, TP53 expression, serum albumin, chemoimmunotherapy, hematopoietic stem cell transplantation, T cells with chimeric antigen receptors therapy, etc. This report will address the progress of HGBL prognosis and therapy in the 58th American Society of Hematology Annual Meeting.
Texto completo:
Disponível
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
Problema de saúde:
Meta 3.8 Atingir a cobertura universal de saúde
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2017
Tipo de documento:
Artigo